Sundaram Senthil Vel's Form 4 filing
Terns Pharmaceuticals, Inc. (TERN) · filed Jun 8, 2022
- Accession no.
- 0001562180-22-004950
- Filed
- Jun 8, 2022
- Trade date
- May 31, 2022
- Filing delay
- 8 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $11.3K. It was filed 8 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sundaram Senthil VelCIK 0001762316 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 31, 2022 | Common Stock | PPurchaseAcquired | +7,656 | $1.47 | +$11,254.32 | 7,656 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Voluntary reporting of ESPP purchase